Skip to main content

What’s New

Latest News

News
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
Oncology
plaque analysis
10/15/2024
WASHINGTON, DC — Four of the seven Medicare Administrative Contractors (MACs) released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). The four contractors for the U.S. Centers for Medicare and Medicaid...
WASHINGTON, DC — Four of the seven Medicare Administrative Contractors (MACs) released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). The four contractors for the U.S. Centers for Medicare and Medicaid...
WASHINGTON, DC — Four of the...
10/15/2024
Cath Lab Digest
Cath Lab Digest
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
Neurology
Clarke joined the team at SCCAD in November 2022, working on the District’s Surge Division and later B-Platoon. He was known for his affable nature and brought a positive energy to the station for every shift.
News
10/15/2024
Clarke joined SCCAD in November 2022 and was known for his affable nature and positive energy.
Clarke joined SCCAD in November 2022 and was known for his affable nature and positive energy.
Clarke joined SCCAD in November...
10/15/2024
EMSWorld
EMSWorld
News
10/11/2024
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
First Report Managed Care
Increase in Suicidality Associated With FDA Black Box Warning Implementation
News
10/11/2024
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on...
10/11/2024
Psych Congress Network
Psych Congress Network
News
10/11/2024
The VA expands tele-emergency care nationwide to improve access to world-class care for veterans.
The VA expands tele-emergency care nationwide to improve access to world-class care for veterans.
The VA expands tele-emergency...
10/11/2024
Veterans Health Today
Veterans Health Today

Latest Research

Volume 32 - Issue 6 - September 2024
Vol. 32, Issue 6, Issue October 2024
Vol. 32, Issue 5, Issue October 2024

HMP Global Learning Network

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Featured Interviews

Dr Craig Chepke
Exclusive Interview
05/21/2024
Meagan Thistle
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
Dr Craig Chepke discusses his...
05/21/2024
Psych Congress Network
Nurses Hoberg and Kempf
Videos
03/21/2024

Featuring Amber Hoberg, PMHNP-BC, and Brooke Kempf, PMHNP-BC

Featuring Amber Hoberg, PMHNP-BC, and...
Nurses Hoberg and Kempf discuss how clinicians and caregivers alike can maintain composure and patience when treating patients with dementia.
Nurses Hoberg and Kempf discuss how clinicians and caregivers alike can maintain composure and patience when treating patients with dementia.
Nurses Hoberg and Kempf discuss...
03/21/2024
Psych Congress Network
Bradley Corr, MD
Conference Coverage
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Constantino Peña, MD, Miami Cancer Institute
Videos
03/21/2024

Featuring Constantino Peña, MD

Featuring Constantino Peña, MD ...
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses...
03/21/2024
IO Learning
Jing-Zhou Hou, MD, PhD
Videos
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
Jack Jennings, MD, PhD, Washington University in St Louis
Videos
02/06/2024

Featuring Jack Jennings, MD, PhD

Featuring Jack Jennings, MD, PhD ...
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting,...
02/06/2024
IO Learning
Saby George, MD
Conference Coverage
01/27/2024

Featuring Saby George, MD 

Featuring Saby George, MD 
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Saby George shares insights from...
01/27/2024
Oncology
Michiel van der Heijden, MD 
Conference Coverage
01/26/2024

Featuring Michiel van der Heijden, MD 

Featuring Michiel van der Heijden, MD...
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology
Thierry André, MD, Saint Antoine Hospital
Videos
01/23/2024

Featuring Thierry André, MD

Featuring Thierry André, MD
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the...
01/23/2024
Oncology
Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
01/23/2024

Featuring Riccardo Lencioni, MD

Featuring Riccardo Lencioni, MD ...
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology

Advertisement

Advertisement